Clinical Trial Update: Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is comparing subcutaneous daratumumab administration in the thigh versus the abdomen for plasma cell disorders, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (Darzalex) (daratumumab)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Plasma Cell Disorder | Phase 1, Phase 2 | Status: RECRUITING